Table 3.
Iron treatment: duration, type of treatment (oral vs. intravenous iron), and dosage
| Crohn (N = 685) | UC (N = 351) | Study Population (N = 1036) | |||
|---|---|---|---|---|---|
| Oral iron, n(%) | 28 | (4.1) | 8 | (2.3) | 36 |
| Daily dosage (mg), n(%) | |||||
| 5 | 1 | (4.8) | 0 | (0.0) | 1 |
| 50 | 2 | (9.5) | 3 | (42.9) | 5 |
| 66 | 1 | (4.8) | 0 | (0.0) | 1 |
| 80 | 10 | (47.6) | 2 | (28.6) | 12 |
| 100 | 1 | (4.8) | 1 | (14.3) | 2 |
| 160 | 4 | (19.0) | 1 | (14.3) | 5 |
| 200 | 1 | (4.8) | 0 | (0.0) | 1 |
| 500 | 1 | (4.8) | 0 | (0.0) | 1 |
| Treatment duration (months), n | 22 | 5 | 27 | ||
| Mean (SD) | 2.8 | (2.5) | 4.6 | (4.4) | 3.1 |
| Median (Q1–Q3) | 3.0 | (1.0;3.0) | 3.0 | (2.0;5.0) | 3.0 |
| [Min–Max] | [1.0–12.0] | [1.0–12.0] | |||
| Intravenous iron, n (%) | 150 | (21.9) | 68 | (19.4) | 218 |
| Sucrose, n (%) | 32 | (23.0) | 12 | (19.0) | 44 |
| Ferric carboxymaltose, n (%) | 118 | (78.7) | 51 | (75.0) | 169 |
| Isomaltose, n (%) | 1 | (0.7) | 1 | (1.6) | 2 |
| Total dosage (mg), n(%) | |||||
| 100 | 5 | (3.4) | 1 | (1.5) | 6 |
| 200 | 14 | (9.4) | 3 | (4.6) | 17 |
| 300 | 9 | (6.0) | 5 | (7.7) | 14 |
| 400 | 1 | (0.7) | 0 | (0.0) | 1 |
| 500 | 21 | (14.1) | 8 | (12.3) | 29 |
| 600 | 3 | (2.0) | 2 | (3.1) | 5 |
| 700 | 0 | (0.0) | 1 | (1.5) | 1 |
| 750 | 1 | (0.7) | 0 | (0.0) | 1 |
| 800 | 1 | (0.7) | 0 | (0.0) | 1 |
| 900 | 4 | (2.7) | 2 | (3.1) | 6 |
| 1000 | 79 | (53.0) | 39 | (60.0) | 118 |
| 1500 | 4 | (2.7) | 1 | (1.5) | 5 |
| 2000 | 4 | (2.7) | 2 | (3.1) | 6 |
| 3000 | 1 | (0.7) | 0 | (0.0) | 1 |
| 4500 | 1 | (0.7) | 0 | (0.0) | 1 |
| 9000 | 1 | (0.7) | 1 | (1.5) | 2 |
UC ulcerative colitis; n number; SD standard deviation; Q quartile